Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shengli Xia

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Journal of Clinical Microbiology|December 4, 2009
Emergence of a new multidrug-resistant serotype X variant in an epidemic clone of Shigella flexneriChangyun Ye, Ruiting Lan, Shengli Xia, et al.
Vaccine|July 9, 2022
Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects ≥3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trialYuhui Zhang, Yanxia Wang, Chunyu Jia, et al.
The Lancet. Infectious Diseases|October 18, 2020
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trialShengli Xia, Yuntao Zhang, Yanxia Wang, et al.
JAMA|August 14, 2020
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical TrialsShengli Xia, Kai Duan, Yuntao Zhang, et al.
Frontiers in Immunology|July 11, 2022
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 TrialShengli Xia, Kai Duan, Yuntao Zhang, et al.
The Lancet. Infectious Diseases|September 18, 2021
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trialShengLi Xia, YunTao Zhang, YanXia Wang, et al.
Eclinicalmedicine|July 12, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trialWanshen Guo, Kai Duan, Yuntao Zhang, et al.
JAMA|May 26, 2021
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical TrialNawal Al Kaabi, Yuntao Zhang, Shengli Xia, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Journal of Clinical Microbiology|December 4, 2009
Emergence of a new multidrug-resistant serotype X variant in an epidemic clone of Shigella flexneriChangyun Ye, Ruiting Lan, Shengli Xia, et al.
Vaccine|July 9, 2022
Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects ≥3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trialYuhui Zhang, Yanxia Wang, Chunyu Jia, et al.
The Lancet. Infectious Diseases|October 18, 2020
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trialShengli Xia, Yuntao Zhang, Yanxia Wang, et al.
JAMA|August 14, 2020
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical TrialsShengli Xia, Kai Duan, Yuntao Zhang, et al.
Frontiers in Immunology|July 11, 2022
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 TrialShengli Xia, Kai Duan, Yuntao Zhang, et al.
The Lancet. Infectious Diseases|September 18, 2021
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trialShengLi Xia, YunTao Zhang, YanXia Wang, et al.
Eclinicalmedicine|July 12, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trialWanshen Guo, Kai Duan, Yuntao Zhang, et al.
JAMA|May 26, 2021
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical TrialNawal Al Kaabi, Yuntao Zhang, Shengli Xia, et al.
Pageof 6